IL23A and Cowden disease: Among the IL-23p19 inhibitors, risankizumab showed a clinical and endoscopic response with a good safety profile and is currently the only drug approved by the FDA and EMA for CD [46] with an induction dose of 600 mg IV at week 0, 4, and 8 followed by 360 mg self-administered via SC injection with an on-body injector (OBI) at week 12 and every 8 weeks thereafter [44,61].